rs1125226 — CYP7A1 CYP7A1 upstream promoter variant

CYP7A1 — The Bile Acid Throttle That Controls LDL Clearance

Your liver is constantly converting cholesterol into bile acids — the detergent-like molecules that emulsify dietary fat and exit the body via the gut. The enzyme that sets the pace for this entire process is cholesterol 7α-hydroxylase¹¹ cholesterol 7α-hydroxylase
CYP7A1 catalyzes the first and rate-limiting step of the classic bile acid synthesis pathway, converting cholesterol to 7α-hydroxycholesterol, encoded by the CYP7A1 gene. The faster this enzyme works, the more cholesterol gets converted to bile acids and cleared, and the lower your LDL tends to be. Variants upstream of CYP7A1 — including rs1125226 — help define haplotypes that collectively tune how much bile acid your liver produces.

The Mechanism

CYP7A1 sits in hepatocyte endoplasmic reticulum membranes and governs the neutral (classic) bile acid pathway²² neutral (classic) bile acid pathway
The classic pathway accounts for ~75% of all bile acid production in humans; the alternative acidic pathway handles the remainder. Its expression is regulated by a network of nuclear receptors: LXRα activates CYP7A1 transcription in response to excess hepatic cholesterol, while FXR (activated by returning bile acids from the gut) represses it as a feedback brake. rs1125226 sits approximately 6.8 kb upstream of the CYP7A1 transcription start site — within the extended promoter/regulatory region — and is a haplotype-tagging SNP for this gene. It was characterised as part of a systematic mapping of CYP7A1's linkage disequilibrium blocks³³ linkage disequilibrium blocks
regions of the genome inherited together more often than chance alone across five population groups.

The rs1125226 A allele co-segregates with specific CYP7A1 promoter haplotypes, of which the well-studied rs3808607 variant is the primary functional site. In hepatocyte assays, the rs3808607 G allele (which travels with certain rs1125226 haplotypes) drives higher CYP7A1 mRNA expression⁴⁴ higher CYP7A1 mRNA expression
Inamine et al. 2013: the G-allele promoter induced significantly higher CYP7A1 expression under both normal and cholestatic conditions than the T allele. The combined two-SNP regulatory model spanning promoter and enhancer spans more than two orders of magnitude in hepatic CYP7A1 expression⁵⁵ two orders of magnitude in hepatic CYP7A1 expression
Wang et al. 2018: only the two-SNP model, not either SNP alone, significantly associated with LDL levels, CAD risk, statin response, and T2D.

The Evidence

A 2023 meta-analysis by Lim et al.⁶⁶ Lim et al.
Lim MYC et al. A meta-analysis of the pooled impact of CYP7A1 single nucleotide polymorphisms on serum lipid responses to statins. Front Genet, 2023 pooled statin-response data and found that CYP7A1 variant carriers had significantly smaller reductions in total cholesterol (WMD −0.17 mmol/L, 95% CI −0.29 to −0.06) and LDL (WMD −0.16 mmol/L, 95% CI −0.26 to −0.05) compared to non-carriers.

Dietary studies add a complementary picture. Wang et al. 2017⁷⁷ Wang et al. 2017
Wang Y et al. Barley β-glucan reduces blood cholesterol levels via interrupting bile acid metabolism. Br J Nutr, 2017 showed that high-molecular-weight barley β-glucan increased bile acid synthesis in all participants, but the effect was "more pronounced" in homozygous G carriers at rs3808607 — the individuals whose CYP7A1 promoter appears most responsive. This genotype-by-diet interaction suggests that dietary cholesterol-lowering strategies targeting bile acid excretion may be especially effective for people whose CYP7A1 is already tuned high.

The earlier Hubacek & Bobkova review⁸⁸ Hubacek & Bobkova review
Hubacek JA, Bobkova D. Role of cholesterol 7alpha-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering. Mol Diagn Ther, 2006 summarised the opposing direction of effect: −204CC homozygotes (at rs3808607) showed the greatest cholesterol reduction from dietary changes, while the −204AA homozygotes responded slightly better to statin therapy. This divergence likely reflects the enzyme's feedback relationship with statins — statins upregulate CYP7A1 as a compensatory mechanism, and individuals with higher baseline CYP7A1 activity may have a ceiling effect.

Direct evidence for rs1125226 alone is limited. The Fu et al. 2011 study⁹⁹ Fu et al. 2011 study
Fu L et al. CYP7A1 genotypes and haplotypes associated with hypertension in an obese Han Chinese population. Hypertens Res, 2011 found no significant independent effect of rs1125226 genotype on hypertension susceptibility, though haplotypes combining rs3808607 and rs1125226 alleles showed significant differences. rs1125226 is best interpreted as a haplotype marker that defines which CYP7A1 regulatory environment you carry, rather than as an independent functional variant.

Practical Actions

For A allele carriers whose haplotype co-occurs with lower CYP7A1 activity signatures, a practical strategy is to emphasise dietary routes that maximise bile acid excretion. Soluble fibre from oats, barley (β-glucan), psyllium, and legumes binds bile acids in the gut and forces the liver to convert more cholesterol to replace them — effectively using diet to compensate for a genetically slower enzymatic throttle. LDL response to statin therapy should be monitored, as meta-analytic data suggest carriers may achieve somewhat smaller LDL reductions at standard doses.

For CC homozygotes, the complementary picture holds: dietary interventions targeting bile acid excretion are likely to be especially responsive, while statin response may be modestly blunted relative to the population average.

Interactions

rs1125226 is a haplotype partner to rs3808607, the CYP7A1 A-204C promoter variant. Their combined haplotype structure is the primary lens through which CYP7A1 regulatory variation should be interpreted — no single SNP in this region tells the whole story. Additionally, CYP7A1 operates at the top of the bile acid synthesis cascade; variants in downstream genes (CYP8B1, BSEP/ABCB11, FXR/NR1H4) and in the cholesterol clearance pathway (APOE rs429358, LDLR) can modify the net effect of CYP7A1 haplotype variation on plasma LDL.